| pubmed-article:10604732 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10604732 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:10604732 | lifeskim:mentions | umls-concept:C0206754 | lld:lifeskim |
| pubmed-article:10604732 | lifeskim:mentions | umls-concept:C0008838 | lld:lifeskim |
| pubmed-article:10604732 | lifeskim:mentions | umls-concept:C0015133 | lld:lifeskim |
| pubmed-article:10604732 | lifeskim:mentions | umls-concept:C0205617 | lld:lifeskim |
| pubmed-article:10604732 | pubmed:issue | 8 | lld:pubmed |
| pubmed-article:10604732 | pubmed:dateCreated | 2000-1-3 | lld:pubmed |
| pubmed-article:10604732 | pubmed:abstractText | The purpose of this study was to evaluate by a retrospective analysis of 53 patients the efficacy of chemotherapy combining etoposide and cisplatin in the treatment of neuroendocrine tumours. The regimen was a combination of etoposide 100 mg m(-2) day(-1) for 3 days and cisplatin 100 mg m(-2) on day 1, given by 2-h intravenous infusion, administered every 21 days. Twelve patients had a well-differentiated and 41 a poorly differentiated neuroendocrine tumour. Toxicity of treatment was assessed in 50 patients and efficacy in 52 patients. Among the 11 patients with a well-differentiated tumour evaluable for tumoural response, only one (9.4%) had a partial response for 8.5 months. Forty-one patients with a poorly differentiated tumour showed an objective response rate of 41.5% (four complete and 13 partial responses); the median duration of response was 9.2 months, the median overall survival 15 months and the median progression-free survival 8.9 months. Haematological grade 3-4 toxicity was observed in 60% of the cases with one treatment-related death, digestive grade 3-4 toxicity in 40% and grade 3 alopecia was constant. No severe renal, hearing and neurological toxicities were observed (grade 1 in 6%, 14%, 72% respectively and no grade >1). We confirm that poorly differentiated neuroendocrine tumours are chemosensitive to the etoposide plus cisplatin combination. However, the prognosis remains poor with a 2-year survival lower than 20% confirming that new therapeutic strategies have to be developed. | lld:pubmed |
| pubmed-article:10604732 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10604732 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10604732 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10604732 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10604732 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10604732 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10604732 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10604732 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10604732 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10604732 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10604732 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10604732 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10604732 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10604732 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10604732 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10604732 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10604732 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10604732 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10604732 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10604732 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10604732 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10604732 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10604732 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10604732 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10604732 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:10604732 | pubmed:issn | 0007-0920 | lld:pubmed |
| pubmed-article:10604732 | pubmed:author | pubmed-author:LasserPP | lld:pubmed |
| pubmed-article:10604732 | pubmed:author | pubmed-author:SchlumbergerM... | lld:pubmed |
| pubmed-article:10604732 | pubmed:author | pubmed-author:DuvillardPP | lld:pubmed |
| pubmed-article:10604732 | pubmed:author | pubmed-author:EliasDD | lld:pubmed |
| pubmed-article:10604732 | pubmed:author | pubmed-author:RougierPP | lld:pubmed |
| pubmed-article:10604732 | pubmed:author | pubmed-author:SabourinJ CJC | lld:pubmed |
| pubmed-article:10604732 | pubmed:author | pubmed-author:DucreuxMM | lld:pubmed |
| pubmed-article:10604732 | pubmed:author | pubmed-author:BaudinEE | lld:pubmed |
| pubmed-article:10604732 | pubmed:author | pubmed-author:AparicioTT | lld:pubmed |
| pubmed-article:10604732 | pubmed:author | pubmed-author:MitryEE | lld:pubmed |
| pubmed-article:10604732 | pubmed:author | pubmed-author:RufiéPP | lld:pubmed |
| pubmed-article:10604732 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10604732 | pubmed:volume | 81 | lld:pubmed |
| pubmed-article:10604732 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10604732 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10604732 | pubmed:pagination | 1351-5 | lld:pubmed |
| pubmed-article:10604732 | pubmed:dateRevised | 2009-11-18 | lld:pubmed |
| pubmed-article:10604732 | pubmed:meshHeading | pubmed-meshheading:10604732... | lld:pubmed |
| pubmed-article:10604732 | pubmed:meshHeading | pubmed-meshheading:10604732... | lld:pubmed |
| pubmed-article:10604732 | pubmed:meshHeading | pubmed-meshheading:10604732... | lld:pubmed |
| pubmed-article:10604732 | pubmed:meshHeading | pubmed-meshheading:10604732... | lld:pubmed |
| pubmed-article:10604732 | pubmed:meshHeading | pubmed-meshheading:10604732... | lld:pubmed |
| pubmed-article:10604732 | pubmed:meshHeading | pubmed-meshheading:10604732... | lld:pubmed |
| pubmed-article:10604732 | pubmed:meshHeading | pubmed-meshheading:10604732... | lld:pubmed |
| pubmed-article:10604732 | pubmed:meshHeading | pubmed-meshheading:10604732... | lld:pubmed |
| pubmed-article:10604732 | pubmed:meshHeading | pubmed-meshheading:10604732... | lld:pubmed |
| pubmed-article:10604732 | pubmed:meshHeading | pubmed-meshheading:10604732... | lld:pubmed |
| pubmed-article:10604732 | pubmed:meshHeading | pubmed-meshheading:10604732... | lld:pubmed |
| pubmed-article:10604732 | pubmed:meshHeading | pubmed-meshheading:10604732... | lld:pubmed |
| pubmed-article:10604732 | pubmed:year | 1999 | lld:pubmed |
| pubmed-article:10604732 | pubmed:articleTitle | Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. | lld:pubmed |
| pubmed-article:10604732 | pubmed:affiliation | Department of Gastroenterology, Institut Gustave Roussy, Villejuif, France. | lld:pubmed |
| pubmed-article:10604732 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10604732 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10604732 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10604732 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10604732 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10604732 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10604732 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10604732 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10604732 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10604732 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10604732 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10604732 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10604732 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10604732 | lld:pubmed |
